Molecular profile
- Sequence
- ZEQLERALNSS
- Molecular Formula
- C51H84N16O21
- Molecular Weight
- 1257.3 g/mol
- PubChem CID
- 91810664
- CAS Number
- 1208243-50-8
- Synonyms
- cibinetide, PH-BSP
Peptide research profile
ARA-290
ARA-290 is a modified form of erythropoietin known for its ability to reduce inflammatory pathways through paracrine signaling and innate repair receptors. Studies have demonstrated that ARA-290 can have positive effects, such as lowering HbA1c levels, enhancing cholesterol profiles, alleviating neuropathic pain, and promoting wound healing. THIS PRODUCT MUST BE RECONSTITUTED WITH PHOSPHATE BUFFERED SALINE!
Dosing literacy
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context—not a protocol or recommendation.
Recorded amount context
Mass amounts available for comparison
- Lower range4 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range8 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Schedule literacy
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Research best practices
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Research orientation
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 01
Research
Scientific studies on ARA-290's effects on blood vessel health and cellular repair
- 02
Reducing Inflammatory Cytokines
ARA-290's effects on inflammatory cytokines and islet cell transplantation
- 03
Tissue Protection
ARA-290's role in tissue protection and immune cell modulation
- 04
Pain Perception
ARA-290's effects on neuropathic pain and small fiber neuropathy
- 05
Orphan Drug
ARA-290's FDA orphan drug status and clinical trial progress
- 06
Summary
Comprehensive overview of ARA-290's therapeutic potential and research status
Evidence map
What is known—and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Source review pending
Research
Scientific studies on ARA-290's effects on blood vessel health and cellular repair
- Source review pending
Reducing Inflammatory Cytokines
ARA-290's effects on inflammatory cytokines and islet cell transplantation
Recorded protocol library
Amounts recorded for ARA-290
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 01
Dose · lower endpoint
4 mg
Sign in for schedule, duration and source context.
- 02
Dose · upper endpoint
8 mg
Sign in for schedule, duration and source context.
Technical reference
Identity, limitations and unknowns
Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Source review
1 links awaiting verification
- Source link · pmc.ncbi.nlm.nih.govVerification pending · Source review pending